Molecular epidemiology of and genetic susceptibility to esophageal cancer

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on clonal evolution in Barrett's carcinogenesis; biomarkers for early detection of esophageal cancer; the role of the methylguanine methyl transferase biomarker in the management of adenocarcinoma; and the discovery of high‐risk genes in families.

[1]  A. Verma,et al.  High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in‐vitro acid and bile exposure in barrett's epithelium cells , 2013, Genes, chromosomes & cancer.

[2]  P. Wen,et al.  The role of MGMT testing in clinical practice: a report of the association for molecular pathology. , 2013, The Journal of molecular diagnostics : JMD.

[3]  Kenneth K Wang,et al.  MicroRNA Expression Signatures during Malignant Progression from Barrett's Esophagus to Esophageal Adenocarcinoma , 2013, Cancer Prevention Research.

[4]  E. Sausville,et al.  A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O6-Methylguanine-DNA Methyltransferase Promoter , 2013, Molecular Cancer Therapeutics.

[5]  Qin Huang,et al.  Structural markers observed with endoscopic 3-dimensional optical coherence tomography correlating with Barrett's esophagus radiofrequency ablation treatment response (with videos). , 2012, Gastrointestinal endoscopy.

[6]  H. Aviv,et al.  Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett’s epithelium , 2012, Molecular Cytogenetics.

[7]  Qin Huang,et al.  Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). , 2012, Gastrointestinal endoscopy.

[8]  Rebecca C Fitzgerald,et al.  Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus , 2012, Nature Medicine.

[9]  Prateek Sharma,et al.  The controversy regarding ablation for Barrett's esophagus without dysplasia , 2011, Current opinion in gastroenterology.

[10]  Rumen Kostadinov,et al.  New Strategies in Barrett's Esophagus: Integrating Clonal Evolutionary Theory with Clinical Management , 2011, Clinical Cancer Research.

[11]  L. Lovat,et al.  Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. , 2011, Gastroenterology.

[12]  D. Whiteman,et al.  Barrett's esophagus , 2011, Journal of gastroenterology and hepatology.

[13]  Shuji Ogino,et al.  MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers , 2011, Cancer Causes & Control.

[14]  D. Banerjee,et al.  Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: A novel in vitro model , 2011, International journal of cancer.

[15]  Xiaohong Li,et al.  A Comprehensive Survey of Clonal Diversity Measures in Barrett's Esophagus as Biomarkers of Progression to Esophageal Adenocarcinoma , 2010, Cancer Prevention Research.

[16]  Sebastian Bauer,et al.  Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome , 2010, Nature Genetics.

[17]  Emily H Turner,et al.  Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome , 2010, Nature Genetics.

[18]  R. Elston,et al.  A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[19]  B. Reid,et al.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.

[20]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[21]  C. Moskaluk,et al.  Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. , 2009, Cancer letters.

[22]  R. Souza,et al.  Repeated exposure to acid and bile selectively induces colonic phenotype expression in a heterogeneous Barrett's epithelial cell line , 2008, Laboratory Investigation.

[23]  Christopher H Contag,et al.  Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. , 2008, Nature medicine.

[24]  N. Fahmy,et al.  Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. , 2007, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[25]  C. Maley,et al.  Cancer as an evolutionary and ecological process , 2006, Nature Reviews Cancer.

[26]  R. Elston,et al.  Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction , 2006, Cancer Epidemiology Biomarkers & Prevention.

[27]  R. Langer,et al.  The prognostic impact of O6‐Methylguanine‐DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma , 2006, International journal of cancer.

[28]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[29]  Michael Vieth,et al.  Prevalence of Barrett's esophagus in the general population: an endoscopic study. , 2005, Gastroenterology.

[30]  M. Pepe,et al.  Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk , 2005, Oncogene.

[31]  P. Malfertheiner,et al.  Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. , 2005, International journal of oncology.

[32]  H. Mashimo,et al.  ALIMENTARY TRACT: ESOPHAGUS Surveillance and Screening for Barrett Esophagus and Adenocarcinoma , 2005 .

[33]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[34]  J. Jankowski,et al.  A family history of Barrett's oesophagus: Another risk factor? , 2005, Scandinavian journal of gastroenterology.

[35]  H. Höfler,et al.  Pathology of upper gastrointestinal malignancies. , 2004, Seminars in oncology.

[36]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[38]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[39]  Yasushi Sano,et al.  American Gastroenterological Association (AGA) Institute technology assessment on image-enhanced endoscopy. , 2008, Gastroenterology.

[40]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.